Hypolipidemic Combination for Diabetic Dyslipidemia

dc.contributor.author	Akramkhuzhaeva A.B
dc.contributor.author	Satibaldieva N.R
dc.contributor.author	Ilmuratova M.A.
dc.date.accessioned	2026-01-02T11:33:16Z
dc.date.issued	2023-09-07
dc.description.abstract	One of the necessary drugs for the treatment of diabetic dyslipidemia affecting lipid metabolism is hydroxycis-methylglutaryl-coenzyme A-reductase inhibitors (statins) [2] and ezetimibe, which blocks the absorption of cholesterol in the epithelium of the small intestine, thereby preventing erythematic enterohepatic circulation of cholesterol [2,4]. Their effectiveness in correcting atherogenic dyslipidemia (DLP) and preventing macroangiopathies has been studied in patients with diabetes mellitus (DM). The aim of this study was to study the lipid-lowering efficacy of the combination therapy of rosuvastatin with ezithymibe in patients with type 2 diabetes mellitus
dc.format	application/pdf
dc.identifier.uri	https://geniusjournals.org/index.php/emrp/article/view/4882
dc.identifier.uri	https://asianeducationindex.com/handle/123456789/77676
dc.language.iso	eng
dc.publisher	Genius Journals
dc.relation	https://geniusjournals.org/index.php/emrp/article/view/4882/4104
dc.source	Eurasian Medical Research Periodical; Vol. 24 (2023): EMRP; 1-7
dc.source	2795-7624
dc.subject	diabetes mellitus
dc.subject	lipid-lowering therapy
dc.title	Hypolipidemic Combination for Diabetic Dyslipidemia
dc.type	info:eu-repo/semantics/article
dc.type	info:eu-repo/semantics/publishedVersion
dc.type	Peer-reviewed Article

item.page.files

pagination.showing.labelpagination.showing.detail

item.page.filesection.name: ab_2023_hypolipidemic_combination_for_diabetic_d.pdf
item.page.filesection.size: 225.34 KB
item.page.filesection.format: Adobe Portable Document Format